Ascendia

  MARKET NEWS

SGS enhances bioanalytical capacity with Saint-Benoît laboratory expansion
Grifols announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in patients with emphysema due to alpha-1 antitrypsin deficiency
Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas
Kupando Announces First Patient Dosed in Phase 1 Clinical Study of Lead Candidate KUP101 in Advanced Solid Tumors
FDA Approves the First Ever mRNA Flu Vaccine From Moderna

  EXPERT CONTENT & RESOURCES

Adare

 

Improving bioavailability using predictive modeling for solubility enhancement

Improving bioavailability using predictive modeling for solubility enhancement

In this case study, predictive modeling with the OSDPredict™ platform was used to prioritize optimal formulation strategies for a program facing low-solubility challenges. This approach improved exposure and supported accelerated advancement toward Phase I clinical trials.

Why Assembly and Packaging Have Become the Critical Path to Drug-Device Launch  

Why Assembly and Packaging Have Become the Critical Path to Drug-Device Launch  

The pharmaceutical industry has spent decades refining drug discovery, biologics manufacturing and fill-finish operations. However, for many combination products today, the greatest risk to launch timelines no longer sits upstream in formulation or production.

Vin Singh Bullfrog AI

BullFrog AI: Applying an End-to-end AI Workflow to Improve Clinical Development 

BullFrog AI Founder and CEO Vin Singh discusses how the company’s end-to-end AI workflow prepares complex clinical data, identifies disease drivers and patient subgroups, and turns those insights into explainable recommendations designed to improve clinical development decisions.

Nina Bauer

Why NAMs Took Decades to Arrive – and Why iPSCs are Making Them Possible

When US and European regulators acted in recent years to support the use of animal model alternatives for drug development, reactions were mixed. There is broad acknowledgement regarding the limitations of animal-based disease models and their inability to fully recapitulate human biological complexity, contributing to a high clinical failure rate, and so there was true excitement for the possibilities.

FDA QSMR Image

Navigating FDA QMSR in 2026 

For years, many medical device manufacturers approached FDA inspections through a familiar lens: prepare documents, review subsystem requirements, rehearse likely questions, and demonstrate compliance against a known framework.

  FEATURED EDITORIAL

  EXPERT INSIGHTS VIDEOS

Mastering Analytics: LC-MS Analysis of Oligonucleotide Drugs

Mastering Analytics: LC-MS Analysis of Oligonucleotide Drugs

  COMPANY PROFILE

Company Logo

Gattefossé provides innovative excipients to human and animal pharmaceutical industries, as well as to the dietary supplements industry. With a service and distribution network that spans over 12 affiliates, 40 distributors, and 90 countries, Gattefossé prides itself on having introduced innovative products tailored to formulators’ needs. We manufacture our products in France, Singapore, and in our new production site in Lufkin, Texas, to better serve our customers all over the world with equivalent high-quality standards.

Click here for more.

 

Company Logo

For over 30 years, Oakwood Chemical has been a trusted supplier of high-quality reagents to academic institutions, chemical manufacturers, and pharmaceutical companies. Based in the scenic South Carolina Lowcountry, our facilities include more than 15,000 square feet of laboratory space and two expansive warehouses totaling 200,000 square feet. With over 150,000 chemicals in stock, we’re ready to meet your needs, whether at the benchtop or production scale.

Click here for more.

 

  WHITEPAPERS & WEBINARS

WEBINAR ON DEMAND: Why early matters: Data-driven strategies to de-risk OSD development

WEBINAR ON DEMAND: Why early matters: Data-driven strategies to de-risk OSD development

Late-stage surprises continue to drive cost, delay, and challenges in oral solid dosage (OSD) development—especially for complex, poorly soluble molecules. Too often, formulation and manufacturability risks surface only after significant time and investment.

In a recent panel discussion, GlobalData’s Director …

WHITEPAPER - An Introduction to PLG Polymers for Long‑Acting Drug Delivery

WHITEPAPER - An Introduction to PLG Polymers for Long‑Acting Drug Delivery

Bioabsorbable poly(lactide-co‑glycolide) (PLG) polymers and poly(lactic acid-co-glycolic acid) (PLGA) have become an essential part of modern healthcare. Over the past five decades, these polymers have transformed how medicines are delivered – enabling long-acting injectables, implants, and localized drug‑delivery products …

WHITEPAPER - From Service Provider to Strategic Partner

WHITEPAPER - From Service Provider to Strategic Partner

By: Tom Sellig, CEO, Adare Pharma Solutions

As drug development grows more complex and timelines compress, sponsors require CDMO relationships built on integration, flexibility, and shared accountability. The relationship between pharmaceutical sponsors and their CDMO partners has undergone a fundamental …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

August 26 – Gene Therapy
September 2 – API Synthesis
September 9 – Bioavailability
September 16 – Capsules